Abstract
It is with great surprise that I read the article on anticysticercal drug therapy by Carpio et al.<sup>1</sup>In that study, anticysticercal drugs were not better than symptomatic therapy for the resolution of parenchymal brain cysticerci and did not modify the clinical course of the disease. These results differ from those reported in most studies about praziquantel or albendazole therapy for parenchymal neurocysticercosis (NC)<sup>2-10</sup>and did not match with those previously reported by the same authors in the same population of patients with NC. In 1988, Carpio et al<sup>11</sup>described 20 patients with parenchymal NC in whom albendazole was highly effective and caused a 84% reduction in the number of brain cysts. Because albendazole has been used to treat human NC since 1986,<sup>3</sup>it must be assumed that those 20 patients had to be included in their 1995 study, because, according to the authors, "Between July
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
